Catalytic mammalian target of rapamycin inhibitors as antineoplastic agents

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• The mammalian target of rapamycin (mTOR) pathway is crucial for regulating mRNA translation and protein production.
• mTOR signaling is implicated in the development of hematological malignancies.
• First-generation mTOR inhibitors (rapalogs) have shown limited clinical efficacy.

Purpose of the Study:

• To review preclinical and clinical investigations of catalytic mTOR inhibitors.
• To summarize potential mechanisms of resistance to these new agents.
• To highlight advancements in targeting the mTOR pathway for hematological cancers.

Main Methods:

• Review of preclinical studies on catalytic mTOR inhibitors.
• Analysis of early-phase clinical trial data.
• Investigation of resistance mechanisms associated with mTOR inhibition.

Main Results:

• Rapalogs provide partial mTORC1 inhibition and do not affect mTORC2.
• Catalytic mTOR inhibitors offer more potent and complete pathway inhibition.
• Emerging data on the efficacy and safety of catalytic mTOR inhibitors are presented.

Conclusions:

• Catalytic mTOR inhibitors represent a promising therapeutic strategy for hematological malignancies.
• Further research is needed to fully understand and overcome resistance mechanisms.
• These novel agents may offer improved clinical outcomes compared to rapalogs.